B7-1/CD80 Antibody (37711) [Unconjugated]

Raji human Burkitt's lymphoma cell line was stained with Mouse Anti-Human B7‑1/CD80 Monoclonal Antibody (Catalog # MAB140, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Fluorescein-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0103B). View our protocol for Staining Membrane-associated Proteins.

B7‑1/CD80 was detected in immersion fixed paraffin-embedded sections of human tonsil using Mouse Anti-Human B7‑1/CD80 Monoclonal Antibody (Catalog # MAB140) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

B7-1/CD80 mRNA was detected in formalin-fixed paraffin-embedded tissue sections of human tonsil probed with ACD RNAScope® Probe (Catalog # 42471) and stained using ACD RNAscope® 2.5 HD Duplex Detection Reagents (red, Catalog # 322500). Adjacent tissue section was processed for immunohistochemistry using R&D Systems Mouse Anti-Human B7-1/CD80 Monoclonal Antibody (Catalog# MAB140) at 5ug/mL with overnight incubation at 4 °C followed by incubation with the Anti-Mouse IgG VisUCyte HRP Polymer Antibody (R&D Systems, Catalog # VC001) and DAB chromogen (lower image, brown). Tissues were counterstained with hematoxylin (blue).

Recombinant Human B7‑1/CD80 Fc Chimera (Catalog # 140-B1) co-stimulates IL‑2 secretion in the Jurkat human acute T cell leukemia cell line in the presence of PHA in a dose-dependent manner (orange line), as measured by the Human IL‑2 Quantikine ELISA Kit (Catalog # D2050). IL‑2 secretion elicited by Recombinant Human B7‑1/CD80 Fc Chimera (1 µg/mL) and PHA (10 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human B7‑1/CD80 Monoclonal Antibody (Catalog # MAB140). The ND50 is typically 0.2-1 µg/mL.

• Reactivity: Hu
• Applications: Flow, IHC, B/N, CyTOF-ready, Dual ISH-IHC, ELISA(Cap)
• Clone: 37711
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

B7-1/CD80 Antibody (37711) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human B7‑1/CD80
  Val35-Asn242 (predicted)
  Accession # P33681
• Specificity: Detects human B7‑1/CD80 in ELISAs. In sandwich immunoassays, no cross-reactivity or interference with recombinant human (rh) B7-2, recombinant mouse (rm) B7-1, rmB7-2, rhB7-H1, rhB7-H2, rhB7-H3 or rmPD-L2 is observed.
• Details of Functionality: ActivityAssaywCitation not found None None None None None
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD80
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunohistochemistry 5-25 ug/mL
  • CyTOF-ready
  • Dxxxxxxxxxxxxxxx 5-25 ug/mL
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.5-2.0 ug/mL
  • Neutralization 0.2-1 ug/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Capture: Human B7-1/CD80 Antibody (Catalog # MAB140)
  ELISA Detection: Human B7-1/CD80 Biotinylated Antibody (Catalog # BAM1402)
  Standard: Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 140-B1)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-1/CD80 Antibody (37711) [Unconjugated]

• Activation B7-1 antigen
• B7
• B71
• B7-1
• BB1
• CD28LG1
• CD28LGB7-1 antigen)
• CD80 antigen
• CD80 molecule
• CD80
• costimulatory factor CD80
• costimulatory molecule variant IgV-CD80
• CTLA-4 counter-receptor B7.1
• T-lymphocyte activation antigen CD80

Background

B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20‑100 fold higher affinity than CD28 and is involved in the down‑regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up‑regulated through Interferon gamma. B7-1 and B7-2 are both members of the Immunoglobulin superfamily. Human B7-1 is a 288 amino acid (aa) protein containing a 34 aa signal peptide, a 208 aa extracellular domain, a 21 aa transmembrane domain, and a 25 aa cytoplasmic domain. Human B7-1 and B7-2 share 26% aa sequenceidentity. Human and mouse B7-1 share 44% aa sequenceidentity. However, it has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.

1. Azuma, M. et al. (1993) Nature 366:76.
2. Freeman, G.J. et al. (1993) Science 262:909.
3. Freeman, G. et al. (1991) J. Exp. Med. 174:625.
4. Selvakumar, A. et al. (1993) Immunogenetics 38:292.
5. Chen, C. et al. (1994) J. Immunol. 152:4929.
6. Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for B7-1/CD80 Antibody (MAB140)(9)

Publications using MAB140

• S Minamikawa, K Nozu, S Maeta, T Yamamura, K Nakanishi, J Fujimura, T Horinouchi, C Nagano, N Sakakibara, H Nagase, H Shima, K Noda, T Ninchoji, H Kaito, K Iijima The utility of urinary CD80 as a diagnostic marker in patients with renal diseases Sci Rep, 2018;8(1):17322. 2018 [PMID: 30470792] (ELISA Development (Detection), Human)
• J Li, SQ Xu, YM Zhao, S Yu, LH Ge, BH Xu Comparison of the biological characteristics of human mesenchymal stem cells derived from exfoliated deciduous teeth, bone marrow, gingival tissue, and umbilical cord Mol Med Rep, 2018;0(0):. 2018 [PMID: 30272340] (Flow Cytometry, Human)
• S He, C Wu, J Xiao, D Li, Z Sun, M Li Endothelial extracellular vesicles modulate the macrophage phenotype: Potential implications in atherosclerosis Scand. J. Immunol., 2018;0(0):. 2018 [PMID: 29465752] (Flow Cytometry, Human)
• SW Lee, SH Baek, JH Paik, S Kim, KY Na, DW Chae, HJ Chin Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients Sci Rep, 2017;7(0):41859. 2017 [PMID: 28150736] (IHC-P, Human)
• Xiongbiao Wang Autoantibodies against CD80 in patients with COPD Clin Transl Immunology, 2016;5(10):e103. 2016 [PMID: 27867516] (Western Blot, Human)
• Mao C, Mou X, Zhou Y, Yuan G, Xu C, Liu H, Zheng T, Tong J, Wang S, Chen D Tumor-activated TCRgammadelta(+) T cells from gastric cancer patients induce the antitumor immune response of TCRalphabeta(+) T cells via their antigen-presenting cell-like effects. J Immunol Res, 2014;2014(0):593562. 2014 [PMID: 24741609] (Functional Assay, Human)
• B7-CD28 costimulatory signals control the survival and proliferation of murine and human gammadelta T cells via IL-2 production. J. Immunol., 2012;189(3):1202-8. 2012 [PMID: 22732586] (Neutralization, Human)
• ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation. Blood, 2012;119(26):6268-77. 2012 [PMID: 22577174] (Neutralization, Human)
• Kosaka K, Yashiro M, Sakate Y, Hirakawa K A synergistic antitumor effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma. Dig. Dis. Sci., 2007;52(8):1946-53. 2007 [PMID: 17404853] (Neutralization, Human)

Bioinformatics

• Gene Symbol: CD80
• Uniprot:
  • P33681()